AU2023250819A1 - Combination therapies comprising a sos1 inhibitor and an egfr inhibitor - Google Patents

Combination therapies comprising a sos1 inhibitor and an egfr inhibitor Download PDF

Info

Publication number
AU2023250819A1
AU2023250819A1 AU2023250819A AU2023250819A AU2023250819A1 AU 2023250819 A1 AU2023250819 A1 AU 2023250819A1 AU 2023250819 A AU2023250819 A AU 2023250819A AU 2023250819 A AU2023250819 A AU 2023250819A AU 2023250819 A1 AU2023250819 A1 AU 2023250819A1
Authority
AU
Australia
Prior art keywords
inhibitor
sos1
pharmaceutically acceptable
egfr inhibitor
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023250819A
Other languages
English (en)
Inventor
Jacob HALING
Shilpi KHARE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirati Therapeutics Inc
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of AU2023250819A1 publication Critical patent/AU2023250819A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2023250819A 2022-04-08 2023-03-13 Combination therapies comprising a sos1 inhibitor and an egfr inhibitor Pending AU2023250819A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263329090P 2022-04-08 2022-04-08
US63/329,090 2022-04-08
PCT/US2023/015097 WO2023196086A2 (en) 2022-04-08 2023-03-13 Combination therapies comprising a sos1 inhibitor and an egfr inhibitor

Publications (1)

Publication Number Publication Date
AU2023250819A1 true AU2023250819A1 (en) 2024-09-26

Family

ID=88243368

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023250819A Pending AU2023250819A1 (en) 2022-04-08 2023-03-13 Combination therapies comprising a sos1 inhibitor and an egfr inhibitor

Country Status (10)

Country Link
US (1) US20250177410A1 (https=)
EP (1) EP4504171A4 (https=)
JP (1) JP2025512999A (https=)
KR (1) KR20240170920A (https=)
CN (1) CN119031916A (https=)
AU (1) AU2023250819A1 (https=)
CA (1) CA3245678A1 (https=)
IL (1) IL315645A (https=)
MX (1) MX2024012445A (https=)
WO (1) WO2023196086A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022271679A1 (en) * 2021-06-21 2022-12-29 Mirati Therapeutics, Inc. Sos1 inhibitors
WO2025090810A1 (en) * 2023-10-25 2025-05-01 Kumquat Biosciences Inc. Use of sos1 inhibitors and amivantamab to treat cancer
WO2025090808A1 (en) * 2023-10-25 2025-05-01 Kumquat Biosciences Inc. Combinations of sos-1 inhibitors with osimertinib and/or met inhibitors to treat cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1833803A4 (en) * 2005-01-03 2009-08-05 Myriad Genetics Inc PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCTORS OF APOPTOSIS AND THEIR USE
WO2016077793A1 (en) * 2014-11-14 2016-05-19 Children's Hospital Medical Center Sos1 inhibitors for cancer treatment
EP3558979B1 (en) * 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
PH12022551513A1 (en) * 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
WO2022083657A1 (zh) * 2020-10-20 2022-04-28 苏州泽璟生物制药股份有限公司 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
CA3221608A1 (en) * 2021-06-14 2022-12-22 Kumquat Biosciences Inc. Fused heteroaryl compounds useful as anticancer agents

Also Published As

Publication number Publication date
MX2024012445A (es) 2024-11-08
CA3245678A1 (en) 2023-10-12
JP2025512999A (ja) 2025-04-22
US20250177410A1 (en) 2025-06-05
IL315645A (en) 2024-11-01
WO2023196086A2 (en) 2023-10-12
EP4504171A4 (en) 2026-03-18
WO2023196086A3 (en) 2023-12-07
EP4504171A2 (en) 2025-02-12
CN119031916A (zh) 2024-11-26
KR20240170920A (ko) 2024-12-05

Similar Documents

Publication Publication Date Title
KR102871791B1 (ko) 병용 요법
EP3849537B1 (en) Combination therapies
AU2022361380A1 (en) Combination therapies of kras g12d inhibitors with sos1 inhibitors
US20250177410A1 (en) Combination therapies comprising a sos1 inhibitor and an egfr inhibitor
JP2022500384A (ja) 組み合わせ療法
JP2022500385A (ja) 組み合わせ療法
US20240408099A1 (en) COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH Pan ErbB FAMILY INHIBITORS
JP2022500381A (ja) 組み合わせ療法
US12280055B2 (en) Combination therapies
US20250186453A1 (en) Combination therapies comprising a sos1 inhibitor and a mek inhibitor
HK40109894A (zh) Kras g12d抑制剂与泛erbb家族抑制剂的组合疗法
HK40101229A (zh) 组合疗法
EA048458B1 (ru) Способы комбинированной терапии